AlphaMark Advisors LLC Sells 550 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

AlphaMark Advisors LLC reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 58.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 395 shares of the medical equipment provider’s stock after selling 550 shares during the quarter. AlphaMark Advisors LLC’s holdings in Zimmer Biomet were worth $42,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ZBH. Equity Investment Corp purchased a new position in shares of Zimmer Biomet during the third quarter worth about $70,104,000. Hotchkis & Wiley Capital Management LLC grew its stake in Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after buying an additional 577,320 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after buying an additional 411,163 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Zimmer Biomet during the 3rd quarter valued at $41,588,000. Finally, FMR LLC lifted its holdings in shares of Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after acquiring an additional 162,384 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $110.78 on Monday. The company has a market cap of $22.05 billion, a PE ratio of 21.06, a P/E/G ratio of 1.88 and a beta of 1.02. The business has a 50 day moving average of $107.86 and a 200 day moving average of $108.13. Zimmer Biomet Holdings, Inc. has a 52 week low of $100.67 and a 52 week high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the firm posted $1.65 EPS. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is presently 18.25%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ZBH. Raymond James lowered their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. BTIG Research dropped their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Truist Financial increased their price target on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Royal Bank of Canada boosted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Finally, Evercore ISI decreased their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.